langerhans cell histiocytosis i2 王鐘慶. introduction accumulation and infiltration of monocytes,...

Langerhans Cell Histiocytosis

I2 王鐘慶

Introduction

Accumulation and infiltration of monocytes, macrophages, and dendritic cells in the affected tissues

Classification of Histiocytosis Syndromes in Children

Class Syndrome

I LCH

II Histiocytosis of mononuclear phagocytes other than Langerhans cells

Hemophagocytic lymphohistiocytosis (familial and reactive)

Sinus histiocytosis with massive lymphadenopathy (Rosai- Dorfman disease)

Juvenile xanthogranuloma

Reticulohistiocytoma

III Malignant histiocytic disorders

Acute monocytic leukemia (FAB M5)

Malignant histiocytosis

True histiocytic lymphoma

Classification of Histiocytosis

H&E (left) demonstrates characteristic giant cells (large arrow), eosinophil infiltrate (eosinophil demonstrated between two small arrows), as well as lymphocytes (single small arrow). Positive CD1a immunohistochemistry (right) demonstrates characteristic membranous staining.

EM demonstrating ultrastructural Birbeck granules (cluster between two arrows).

Writing Group of the Histiocyte Society : diagnosis of class I LCH

Presumptive diagnosis - Light morphologic characteristics Designated diagnosis - Light morphologic features plus 2 or

more supplemental positive stains for the following: Adenosinetriphosphatase S-100 protein a-D-Mannosidase Peanut lectin

Definitive diagnosis - Light morphologic characteristics plus Birbeck granules in the lesional cell with electron microscopy and/or staining positive for CD1a antigen (T6) on the lesional cell

Categories of Langerhans’ Cell Histiocytosis (LCH)

Based on the severity and extent of involvement Letterer-Siwe disease Eosinophilic granulomas Hand-Schuller-Christian disease Hashimoto-Pritzker disease

Evaluate the extent of involvement and its relationship to prognosis (modified from Egeler and D'Angio classification) Restricted LCH

Skin lesions without any other site of involvement Monostotic lesion with or without diabetes insipidus, adjacent lymph node involvement, or rash Polyostotic lesions involving several bones or more than 2 lesions in one bone, with or without diabetes i

nsipidus, adjacent lymph node involvement, or rash Extensive LCH

Visceral organ involvement with or without bone lesions, diabetes insipidus, adjacent lymph node involvement, and/or rash but without signs of organ dysfunction of the lungs, liver, or hemopoietic system

Visceral organ involvement with or without bone lesions, diabetes insipidus, adjacent lymph node involvement, and/or rash but with signs of organ dysfunction of the lungs, liver, or hematopoietic system

Location of lesions and extent of the disease have a significant effect on the course of the disease and prognosis

Unifocal LCH (eosinophilic granuloma of bone)

Age: 5-15 years Solitary calvarial lesion in young adu

lts; other sites of involvement include the vertebra, the rib, the mandible, the femur, the ilium, and the scapula .

Asymptomatic or painful.

Multifocal LCH (Hand-Schuller-Christian disease) Age: 2-10 years Fever, diffuse eruption(scalp, ear canal), o

titis media, mastoiditis, URI, bone lesions, mild lymphadenopathy, hepatomegaly, and splenomegaly.

Diabetes insipidus (posterior stalk of the hypothalamus)

Hand-Schűller-Christian triad: calvarial bone defects, diabetes insipidus, exophthalmos

Acute disseminated LCH (Letter-Siwe disease) Age: <2 y/o Aggressive systemic disorder fever; anemia; thrombocytopenia;

pulmonary infiltrates; skin lesions; and enlargement of the lymph nodes, the spleen, and the liver

Rapid fatal if untreated With intensive chemotherapy, 5-year survival

is about 50%

Clinical Presentation

Bone Skin Hypothalamic/Pituitary axis Other endocrinopathies CNS Lymph nodes Hepatic enlargement Others

Bone

The most common manifestation (80~100% )

Skull (27%), femur (13%), mandible/maxilla (11%), pelvis (10%), vertebral bodies (8%), ribs (8%), humerus (5%), and tibia (3%)

The bones of the hands and feet usually spared.

Skin

Up to 50% with multisystem disease may initially present with a rash.

Often the first sign of multisystem LCH Scaly, erythematous, seborrhea-like brown t

o red papules, presenting in a fashion similar to contact dermatitis

Hypothalamic/Pituitary axis

Hypothalamic involvement:disturbances in behavior, appetite, temperature regulation, or sleep patterns.

Posterior pituitary involvement: DI

Other endocrinopathies

Growth retardation Thyroid hormone deficiency Precocious or delayed puberty, ameno

rrhea, and hypocortisolism

CNS

Cognitive impairment, emotional lability, changes in behavior, neurologic dysfunction, pyramidal signs, cerebellar symptoms, and cranial nerve palsy (causing difficulties in speech and swallowing)

The most common manifestation is cerebellar symptoms, followed by pyramidal signs and cranial nerve palsy

Lymph node

Lymph nodes are sometimes enlarged in LCH patients (less than 10%), with those from the head and neck region preferentially affected

Hepatic enlargement

Very common in people with disseminated disease (up to 1/3 to 1/2 of children with disseminated disease have hepatomegaly) Signify a later stage of multisystemic disease or a manifestation of a more fulminant disease process

Lung disease

Respiratory distress with tachypnea, retraction, and persistent cough

lung disease is most common in adult LCH patients.

Children with uncontrolled LCH may develop chronic respiratory failure, presenting with cysts or bullae

Others

Otitis Hypertrophic gingivitis Oral manifestations may result in bleeding g

ums, early eruption, or even loss of teeth GI involvement rare (the most common pre

senting sign is "failure to thrive" due to malabsorption)

Treatment Single-agent chemotherapy is the first l

ine therapy.(carboplatin, 2-chlorodeoxyadenosine, chlorambucil, cyclophosphamide, cytosin, arabinoside, daunomycin, etoposide, mercaptopurine, methotrexate, mechlorethamine, procarbazine, vinblastine, vincristine, vindesine)

Topical steroid, intralesional injection of steroids, NSAID, phototherapy, bone marrow allografting, hematopoietic stem cell transplantation, cyclosporin A,prednisoe.